Pericytic mimicry in well-differentiated liposarcoma / atypical lipomatous tumor

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.humpath.2016.03.008

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Human pathology

Publisher Rights Statement:
Author's final peer-reviewed manuscript as accepted for publication

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Accepted Manuscript

Pericytic mimicry in well-differentiated liposarcoma / atypical lipomatous tumor

Jia Shen PhD, Swati Shrestha BS, P. Nagesh Rao PhD, Greg Asatrian BS, Michelle A. Scott DDS, MBA, Vi Nguyen BS, Paulina Giacomelli BS, Chia Soo MD, Kang Ting DMD, DMedSci, Fritz C. Eilber MD, Bruno Peault PhD, Sarah M. Dry MD, Aaron W. James MD

PII: S0046-8177(16)30021-1
DOI: doi: 10.1016/j.humpath.2016.03.008
Reference: YHUPA 3859

To appear in: Human Pathology

Received date: 15 December 2015
Revised date: 1 March 2016
Accepted date: 3 March 2016

Please cite this article as: Shen Jia, Shrestha Swati, Rao P. Nagesh, Asatrian Greg, Scott Michelle A., Nguyen Vi, Giacomelli Paulina, Soo Chia, Ting Kang, Eilber Fritz C., Peault Bruno, Dry Sarah M., James Aaron W., Pericytic mimicry in well-differentiated liposarcoma / atypical lipomatous tumor, Human Pathology (2016), doi: 10.1016/j.humpath.2016.03.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Pericytic mimicry in well-differentiated liposarcoma / atypical lipomatous tumor

Jia Shen Ph.D.1,* Swati Shrestha, B.S.2,* P. Nagesh Rao, Ph.D.2, Greg Asatrian, B.S.1,2, Michelle A. Scott, D.D.S, M.B.A.3, Vi Nguyen, B.S.2, Paulina Giacomelli, B.S.2, Chia Soo, M.D.4,5, Kang Ting, D.M.D., D.Med.Sci.1, Fritz C. Eilber, M.D.5, Bruno Peault, Ph.D.4,6, Sarah M. Dry, M.D.2, Aaron W. James, M.D.1,2,4#

1 School of Dentistry, University of California, Los Angeles, 90095; 2 Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095; 3 Nationwide Children’s Hospital, Columbus, Ohio, 43205; 4 Orthopedic Hospital Research Center, University of California, Los Angeles, 90095; 5 Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA, 90095; 6 Center for Regenerative Medicine, University of Edinburgh, Edinburgh, UK

*The authors share equal responsibility for the work presented herein

Running Head: Pericyte mimicry in liposarcoma

#Correspondence:
Aaron W. James, M.D.
Department of Pathology & Laboratory Medicine
University of California, Los Angeles, David Geffen School of Medicine
10833 Le Conte Ave., 13-145 CHS
Los Angeles, California 90095
Tel: (310) 206-6754
Email: Awjames@mednet.ucla.edu
Abstract

Pericytes are modified smooth muscle cells that closely enwrap small blood vessels, regulating and supporting the microvasculature through direct endothelial contact. Pericytes demonstrate a distinct immunohistochemical profile, including expression of αSMA (Smooth Muscle Actin), CD146, PDGFRβ (Platelet Derived Growth Factor Receptor β), and RGS5 (regulator of G-protein signaling 5). Previously, pericyte related antigens have been observed to be present among a group of soft tissue tumors with a perivascular growth pattern, including glomus tumor, myopericytoma and angioleiomyoma. Similarly, malignant tumor cells have been shown to pericyte-like immunoprofile when present in a perivascular location, seen in malignant melanoma, glioblastoma, and adenocarcinoma. Here, we examine well-differentiated liposarcoma specimens, which showed some element of perivascular areas with the appearance of smooth muscle (N=7 tumors). Immunohistochemical staining was performed for pericyte antigens, including αSMA, CD146, PDGFRβ, and RGS5. Results showed consistent pericytic marker expression among liposarcoma tumor cells within a perivascular distribution. MDM2 immunohistochemistry and fluorescence in situ hybridization for MDM2 revealed that these perivascular cells were of tumor origin (7/7 tumors), while double immunohistochemical detection for CD31/CD146 ruled out an endothelial cell contribution. These findings further support the concept of pericytic mimicry, already established in diverse malignancies, and its presence in well-differentiated liposarcoma. The extent to which pericytic mimicry has prognostic significance in liposarcoma is as yet unknown.

Keywords: liposarcoma, pericyte, SMA, CD146, PDGFRB
1. Introduction

Pericytes are modified smooth muscle cells that closely enwrap small blood vessels, regulating and supporting the microvasculature through direct endothelial contact. Pericytes demonstrate a distinct immunohistochemical profile, including expression of αSMA (Smooth Muscle Actin), CD146, PDGFRβ (Platelet Derived Growth Factor Receptor β), and RGS5 (regulator of G-protein signaling 5), without evidence of endothelial differentiation\(^1,^2\). Current interests in pericytes stem in large part from the growing understanding that this cell type represents a native mesenchymal stem cell (MSC) progenitor cell\(^1,^3-^9\). Indeed, purified pericytes give rise to multiple mesodermal tissues after *in vitro* differentiation or *in vivo* transplantation, including bone, adipose, cartilage, and muscle – features identical to traditionally derived bone marrow MSC\(^9,^10\).

Growing data suggests that when tumor cells adopt a perivascular location, they also adopt cell surface markers characteristic of pericytes. This phenomenon is best understood in malignant melanoma, where tumor cells adopt a perivascular migration pattern, or ‘angiotropism’\(^11-^13\). This perivascular invasion, also called extravascular migratory metastasis (EVMM), is an under recognized route of tumor spread, and associated with a poor prognosis in melanoma\(^13\). Similarly, in the malignant brain tumor glioblastoma, tumor cells adopt a pericyte-like location associated with perivascular invasion\(^14,^15\). In fact, using cell-tracking techniques, investigators have found that the majority of vessel-lining pericyte-like cells in glioblastoma are actually of tumor cell origin. Likewise, recent research suggests that pancreatic and prostatic adenocarcinoma exhibit perivascular invasion for regional spread, although this has been less well studied\(^16,^17\). In summary, pericyte marker expression, also termed ‘pericyte mimicry’ is a characteristic finding across all studied tumors with a perivascular tumor growth.

A subset of liposarcomas display heterologous differentiation, including smooth muscle, bone, and cartilage. Non-neoplastic adipose tissue is a rich source of pericytes\(^18-^22\), and it is currently assumed that tissue resident MSC are the precursors for these heterologous components within liposarcoma. Of particular interest are areas with the appearance of smooth muscle within well-differentiated liposarcoma\(^23-^26\). Areas resembling smooth muscle often appear to arise from and radiate outwards from intratumoral blood vessels, usually in a multifocal fashion\(^23\). These perivascular proliferations house atypical stromal cells characteristic of liposarcoma, often within the vessel wall. Of note, these perivascular cells demonstrate immunoreactivity Smooth Muscle Actin (SMA)\(^23\), but a more thorough examination of pericyte markers has not yet been performed.
Here, we examine well-differentiated liposarcoma specimens. We hypothesized that these perivascular areas with the appearance of smooth muscle would be associated with a pericyte immunophenotype, or ‘pericytic mimicry,’ within liposarcoma tumor cells.

2. Materials and Methods

2.1 Tissue Identification and Histology

Tumors were identified using a retrospective review of the pathology slide archives of the Department of Pathology and Laboratory Medicine at the University of California, Los Angeles (UCLA), examining 55 cases with a diagnosis of ‘well-differentiated liposarcoma’ or ‘atypical lipomatous tumor.’ Slides were reviewed by two independent pathologists to ensure accuracy of diagnosis, and to identify tumors with some element of perivascular areas with the appearance of smooth muscle (S.M.D and A.W.J). Cases with dedifferentiation or greater than 5 mitotic figures per 10 HPF were not included. Patient information was obtained, including age, sex, tumor location, tumor size, and previous cytogenetic studies performed during the initial diagnostic evaluation. Formalin fixed paraffin embedded (FFPE) tumor tissue from patients were acquired from the tissue archives, under UCLA IRB approval # 13-000918.

2.2 Immunohistochemistry

Immunohistochemistry for pericyte markers was performed using the ABC method (Vectastain Elite ABC, Vector Laboratories, Burlingame, CA, USA) using DAB as the chromogen (ImmPACT DAB, Vector Laboratories). Multiple antigens were detected by multiplexing the ABC method and DAB chromogen with an alkaline phosphatase polymer detection method (ImmPress-AP Polymer Detection, Anti-mouse IG, Vector Laboratories) and Vector Red® chromogen (Vector Red® Alkaline Phosphatase Substrate, Vector Laboratories).

The following primary antibodies were used: monoclonal mouse anti-MDM2 (1/100, EMD Millipore), monoclonal mouse anti-αSMA (1/75, [1A4], ABCAM), monoclonal rabbit anti-CD146 (1/500, EPR3208, ABCAM, Cambridge, MA, USA), monoclonal rabbit anti-PDGFRβ (1/100, [2E8E1], monoclonal mouse anti-RGS5 (1/100, [89C2], Cell Signaling Technologies), and monoclonal mouse anti-CD31 (1/100, [89C2], Cell Signaling Technologies). The following secondary antibodies were used: polyclonal goat biotinylated anti-rabbit IgG (1/500, Sigma, St. Louis, MO, USA), polyclonal horse anti-mouse IgG (1/500,[H + L], Vector Laboratories), polyclonal goat anti-rat Ig (1/500, Becton Dickinson and Company).
Heat mediated antigen retrieval was performed for all immunohistochemical stains in 1 mM tris-EDTA, 0.01% Tween-20 (Sigma), pH 8. Non-specific antibody binding was blocked (IHC-TEK Antibody Diluent, pH 7.4, IHC World, LLC, Woodstock, MD, USA). Endogenous peroxidase and alkaline phosphatase blocking solution was used (BLOXALL Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution, Vector Laboratories). Mayer’s hematoxylin was used as a nuclear counterstain (1/5, ABCAM) and slides were mounted using an aqueous media (VectaMount AQ, Vector Laboratories). In all cases, immunohistochemical staining without primary antibody was used as a negative control.

2.3 Fluorescence in situ hybridization (FISH)

Fluorescence in situ hybridization (FISH) was performed using commercially available fluorescently labeled dual-color MDM2 (red)/CEP 12 (green) probe sets from Abbott-Molecular, IL, USA. The FISH hybridization and analyses were performed on 2 μm thick formalin fixed paraffin tissue sections, following the manufacturer’s suggested protocols. The cells were counterstained with DAPI (4’,6-diamidino-2-phenylindole) and the red and green fluorescent probe signals were simultaneously observed and imaged under a Zeiss (Axiophot) Fluorescent Microscope equipped with dual- and triple-color filters. A stained slide with the perivascular areas of interest was marked and used for assessing FISH signal patterns. The MDM2 amplified cells exhibited a very high number of red signals relative to the number of centromere control signals (CEP 12). As well as being in greater number, the amplified MDM2 signals were usually smaller and tightly clustered. Representative images of the perivascular areas were captured using a cooled charged coupled device camera.

3. Results

3.1 Perivascular smooth muscle proliferation in well-differentiated liposarcoma / atypical lipomatous tumor (WDLPS / ALT)

Seven cases of WDLPS / ALT with perivascular areas with the appearance of smooth muscle were identified in our retrospective examination of case files (Table 1). Most cases arose in either the retroperitoneum (n=3) or the lower extremity (n=3), and affected individuals were in their 5th to 7th decades of life. Tumors ranged in size from 8.5 - 41 cm in greatest dimension. Clinical follow-up was 13.7 years (range 2-19 years). Two patients suffered local
recurrences (28.5% of cases). Karyotype studies obtained in one case, showed supernumerary ring chromosomes, characteristic of WDLPS / ALT. All cases (100%, 7 of 7) demonstrated amplification of \textit{MDM2} by FISH, which was confirmed by MDM2 immunohistochemistry (100%, 7 of 7).

The histologic appearance of the seven cases of WDLPS / ALT was first examined (Fig. 1). Tumors showed a variable lipomatous to sclerotic background. Perivascular areas with the appearance of smooth muscle were most commonly in a multifocal distribution, often clustered around groups of adjacent blood vessels (black arrowheads, Fig. 1). Enlarged, hyperchromatic and atypical stromal cells characteristic of liposarcoma were found within these perivascular areas (red arrowheads, Fig. 1). These were seen both intimately associated with the endothelium and also at a distance from the vessel wall (compare Fig. 1F to 1E). One case showed patchy heterologous bone formation (not shown).

3.2 \textit{Pericyte marker expression in liposarcoma / atypical lipomatous tumor (WDLPS / ALT)}

Next, pericyte marker expression was evaluated by immunohistochemical stainings. First, perivascular areas were examined (Fig. 2, three representative areas in different tumors shown). In each instance, atypical stromal cells were seen within a perivascular location. Interestingly, these atypical stromal cells were found to be frequently positive for the majority of pericyte antigens (Fig. 2D-L, black arrowheads). This included consistent immunoreactivity for αSMA, CD146, and RGS5. Of note, PDGFRβ showed minimal staining in most cases (not shown).

Next, areas within the tumor substance and apart from prominent vasculature were examined (Fig. 3). For the most part, pericyte antigens were not commonly seen among lipoblasts or enlarged stromal cells within WDLPS / ALT apart from the perivascular areas. However, on detailed examination, rare to scattered atypical stromal cells were seen with pan-positivity for pericyte markers (αSMA, CD146, RGS5, and PDGFRβ shown, black arrowheads).

3.3 \textit{Confirmation of tumor cell origin among perivascular cells}

Nuclear enlargement and hyperchromasia among perivascular cells has previously led to the assumption that these were of tumor cell origin \textsuperscript{23}. In order to confirm this, markers of endothelial differentiation (CD31) and
liposarcomatous origin (MDM2 gene amplification and MDM2 expression by IHC) were assayed (Fig. 4). First, dual immunohistochemistry was performed for CD31 (highlighting endothelium red) and CD146 (highlighting perivascular cells in brown) (Fig. 4A,B). As expected CD31 immunostaining was restricted to the endothelium, while CD146 highlighted both perivascular and endothelial cells. Next, MDM2 amplification within perivascular cells was assayed by fluorescence in situ hybridization (Fig. 4C,D). A marked increase in MDM2 signals (red) was observed among perivascular tumor cells (vascular lumen highlighted with dashed white lines). These findings were confirmed with MDM2 immunohistochemical staining, demonstrating atypical perivascular cells with nuclear MDM2 immunoreactivity (Fig. 4E,F). In aggregate, these studies confirm the tumor cell origin of perivascular cells with pericyte antigen expression in WDLPS / ALT.

4. Discussion

In summary, pericyte antigen expression is present among WDLPS / ALT tumor cells and is found predominantly in a perivascular distribution. Scattered single atypical stromal cells unassociated with vascular smooth muscle proliferation also showed pericyte antigen expression, albeit less frequently. The presence of multiple pericyte antigens among these vasculature-associated atypical stromal cells has strong parallels to pericytic mimicry, a phenomenon best described in malignant melanoma. Pericytic mimicry has also been termed extravascular migratory metastasis (EVMM) or angiotropism. In general, angiotropic tumor cells are defined histologically as tumor cells closely associated with the endothelium of vascular channels in a pericytic location, and do not show intravasation into the blood vessel. While in melanoma, pericytic mimicry is generally described at the advancing front of the tumor, in WDLPS / ALT this phenomenon was observed in a multicentric fashion in association with the vasculature.

Pericytic mimicry has been shown to be an independent poor prognostic marker in melanoma. Specifically, analysis of 52 patients with malignant melanoma showed a significant association between angiotropism and development of metastasis, with other prognostic features such as tumor thickness being identical. Although somewhat limited in number, our cases followed a typical disease course for WDLPS / ALT, characterized by local recurrence in 2/7 cases (28.5%). Of note, Gronchi et al. recently found that myogenic differentiation was associated with a poor prognosis in retroperitoneal liposarcoma. However this study examined both well-
differentiated and dedifferentiated tumors, and included both markers of smooth and skeletal muscle differentiation. Thus, we consider this ‘myogenic differentiation’ wholly distinct from pericytic mimicry.

In our previous reports, we examined pericyte antigen expression among soft tissue tumors with a perivascular growth pattern. These included glomus tumor, myopericytoma, and angioleiomyoma. Results showed that among all tumors a consistent expression pattern of pericyte markers was observed in relation to their perivascular pattern of growth, including diffuse immunoreactivity for αSMA, CD146, and PDGFRβ. Later studies found that angiomyolipoma and related PEComa family tumors showed relatively consistent, although patchy, pericytic marker expression. These expression patterns are distinct from the predominantly perivascular distribution of pericyte antigens in WDLPS / ALT.

Unfortunately, no known pericytic markers are absolutely specific. For example, RGS5 expression has been observed in a number of malignancies, including lung, gastric, and hepatocellular carcinomas, as well as various lymphomas. Likewise, CD146 expression can be found in mucoepidermoid carcinoma, gestational trophoblastic tumors, angiosarcoma, and Kaposi’s sarcoma, among other tumor types. However, based on the available literature and the present study, co-expression of multiple pericyte markers (including αSMA, CD146, PDGFRβ, and RGS5) is quite specific for pericytic differentiation. Other possible pericyte markers have yet to be investigated in soft tissue tumors, including Ang-1, Ang-2, and Nestin.

In summary, pericyte antigen expression is present among WDLPS / ALT tumor cells and is found predominantly in a perivascular distribution. This phenomenon parallels pericyte mimicry, found in melanoma and other malignant neoplasms. The extent to which pericytic mimicry has prognostic significance in liposarcoma is as yet unknown.

Disclosure/Conflict of Interest
The authors have no conflicts of interest.

Acknowledgements
The present work was supported by the UCLA Daljit S. and Elaine Sarkaria Fellowship award, the Orthopaedic Research and Education Foundation with funding provided by the Musculoskeletal Transplant Foundation, and
NIH/NIAMS K08 AR068316. The authors thank the staff of UCLA Translational Pathology Core Laboratory, Y. Yen, and A.S. James for their excellent technical assistance.

References


### Table 1: Patient demographics

<table>
<thead>
<tr>
<th>Sample #</th>
<th>Diagnosis</th>
<th>Gender (M/F)</th>
<th>Age (yrs)</th>
<th>Location</th>
<th>Size (cm)</th>
<th>Recurrence</th>
<th>Time to recurrence (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ALT</td>
<td>M</td>
<td>65</td>
<td>Thigh</td>
<td>25</td>
<td>No</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>LPS, WD</td>
<td>M</td>
<td>64</td>
<td>Retroperitoneum</td>
<td>24</td>
<td>No</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>LPS, WD</td>
<td>F</td>
<td>54</td>
<td>Retroperitoneum</td>
<td>25</td>
<td>Yes</td>
<td>93</td>
</tr>
<tr>
<td>4</td>
<td>ALT</td>
<td>F</td>
<td>43</td>
<td>Back</td>
<td>8.5</td>
<td>No</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>LPS, WD</td>
<td>M</td>
<td>58</td>
<td>Retroperitoneum</td>
<td>11</td>
<td>Yes</td>
<td>20</td>
</tr>
<tr>
<td>6</td>
<td>ALT</td>
<td>F</td>
<td>53</td>
<td>Calf</td>
<td>20</td>
<td>No</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>ALT</td>
<td>M</td>
<td>63</td>
<td>Thigh</td>
<td>41</td>
<td>No</td>
<td>-</td>
</tr>
</tbody>
</table>

ALT: Atypical lipomatous tumor; LPS: Liposarcoma; WD: Well-differentiated
Figure Legends

Fig. 1 Appearance of liposarcoma / atypical lipomatous tumor. (A-F) Histological appearance of well-differentiated liposarcoma / atypical lipomatous tumor, by H&E staining. Areas of variably prominent perivascular smooth muscle differentiation were imaged, including atypical stromal cells in proximity to these areas. Red arrowheads indicate atypical enlarged stromal cells, while black arrowheads indicate areas of perivascular smooth muscle differentiation. Black scale bar: 100 μm. White scale bar: 500 μm.

Fig. 2 Pericytic markers in liposarcoma / atypical lipomatous tumor. (A-C) H&E appearance. (D-F) α Smooth Muscle Actin (αSMA) immunohistochemical staining. (G-I) RGS5 immunohistochemical staining. (J-L) CD146 immunohistochemical staining. Black arrowheads indicate atypical enlarged stromal cells with positive staining. Black scale bar: 100 μm.

Fig. 3 Pericytic markers in liposarcoma / atypical lipomatous tumor. (A,B) H&E appearance. (C,D) α Smooth Muscle Actin (αSMA) immunohistochemical staining. (E,F) RGS5 immunohistochemical staining. (G,H) CD146 immunohistochemical staining. (I,J) PDGFRβ immunohistochemical staining. Black arrowheads indicate atypical enlarged stromal cells with positive staining. Black scale bar: 100 μm.

Fig. 4 Tumor cell origin of perivascular cells in liposarcoma / atypical lipomatous tumor. (A,B) Dual immunohistochemical staining for CD31 (endothelial marker, appearing red) and CD146 (pericyte marker, appearing brown). Please note that CD146 is known to also highlight endothelial cells. (C,D) MDM2 amplification by Fluorescence In Situ Hybridization. MDM2 appears red, CEP 12 appears green, and DAPI nuclear counter stain appears blue. White dashed lines highlight vascular lumen. (E,F) Nuclear MDM2 immunohistochemical staining. Black and white arrowheads indicate atypical enlarged stromal cells with positive staining. Black scale bar: 100 μm.
Figure 1

(A) Image with pink and white patterns and small black arrows.
(B) Image with pink and white patterns and a red arrow.
(C) Image with pink and white patterns and a black arrow.
(D) Image with pink and white patterns and a black arrow.
(E) Image with purple and white patterns and a red arrow.
(F) Image with pink and white patterns and red arrows.
Figure 2

A. H&E staining showing cellular detail.

B. H&E staining with increased magnification.

C. H&E staining highlighting tissue structure.

D. αSMA immunostaining indicating smooth muscle cells.

E. αSMA immunostaining with higher magnification.

F. αSMA immunostaining showing cell nuclei.

G. RGS5 immunostaining with cellular detail.

H. RGS5 immunostaining at higher magnification.

I. RGS5 immunostaining highlighting specific areas.

J. CD146 immunostaining with cell markers.

K. CD146 immunostaining at higher magnification.

L. CD146 immunostaining showing distinct regions.
Figure 3

A

H&E

B

C

αSMA

D

E

RGSS5

F

G

CD146

H

I

PDGFRβ

J
Figure 4

A

B

C

D

E

F
Highlights

• Pericyte mimicry has been studied in melanocytic but not mesenchymal tumors
• Liposarcoma shows aberrant pericyte markers in a perivascular fashion
• Pericyte mimicry is present in cells of liposarcoma rather than endothelial origin